Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity, and cognitive dysfunction.

The Hypoglycemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Key Targets in the Hypoglycemia Pipeline Products Market

The key targets in the Hypoglycemia pipeline products market are Glucagon Receptor, Glucagon Like Peptide 1 Receptor, Glucose Dependent Insulinotropic Receptor, Insulin Receptor, Sodium/Glucose Cotransporter 2, and Somatostatin Receptor Type 2.

Hypoglycemia Pipeline Products Analysis Market by Targets

Hypoglycemia Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Hypoglycemia Pipeline Products Market

The key mechanisms of action in the Hypoglycemia pipeline products market are Glucagon Receptor Agonist, Glucagon Like Peptide 1 Receptor Antagonist, Glucose Dependent Insulinotropic Receptor Agonist, Insulin Receptor Antagonist, Sodium/Glucose Cotransporter 2 Inhibitor, and Somatostatin Receptor Type 2 Antagonist.

Hypoglycemia Pipeline Products Market Analysis by Mechanism of Actions

Hypoglycemia Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Hypoglycemia Pipeline Products Market

The key routes of administration in the Hypoglycemia pipeline products market are subcutaneous, intravenous, intramuscular, oral, parenteral, and transdermal.

Hypoglycemia Pipeline Products Market Analysis by Routes of Administration

Hypoglycemia Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Hypoglycemia Pipeline Products Market

The key molecule types in the Hypoglycemia pipeline products market are recombinant peptide, synthetic peptide, monoclonal antibody, and small molecule.

Hypoglycemia Pipeline Products Market Analysis by Molecule Type

Hypoglycemia Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Hypoglycemia Pipeline Products Market

Some of the major companies in the Hypoglycemia pipeline products market are LATITUDE Pharmaceuticals Inc, Avolynt Inc, Boehringer Ingelheim International GmbH, Covis Pharmaceuticals Inc, CymaBay Therapeutics Inc, Eiger BioPharmaceuticals Inc, NB Health Laboratory Co Ltd, Protomer Technologies Inc, Rezolute Inc, and Twist Bioscience Corp.

Hypoglycemia Pipeline Products Market Analysis by Companies

Hypoglycemia Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Glucagon Receptor, Glucagon Like Peptide 1 Receptor, Glucose Dependent Insulinotropic Receptor, Insulin Receptor, Sodium/Glucose Cotransporter 2, and Somatostatin Receptor Type 2
Key mechanism of action Glucagon Receptor Agonist, Glucagon Like Peptide 1 Receptor Antagonist, Glucose Dependent Insulinotropic Receptor Agonist, Insulin Receptor Antagonist, Sodium/Glucose Cotransporter 2 Inhibitor, and Somatostatin Receptor Type 2 Antagonist
Key routes of administration Subcutaneous, Intravenous, Intramuscular, Oral, Parenteral, and Transdermal
Key molecule type Recombinant Peptide, Synthetic Peptide, Monoclonal Antibody, and Small Molecule
Major companies LATITUDE Pharmaceuticals Inc, Avolynt Inc, Boehringer Ingelheim International GmbH, Covis Pharmaceuticals Inc, CymaBay Therapeutics Inc, Eiger BioPharmaceuticals Inc, NB Health Laboratory Co Ltd, Protomer Technologies Inc, Rezolute Inc, and Twist Bioscience Corp

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Avolynt Inc
Boehringer Ingelheim International GmbH
Covis Pharmaceuticals Inc
CymaBay Therapeutics Inc
Eiger BioPharmaceuticals Inc
LATITUDE Pharmaceuticals Inc
NB Health Laboratory Co Ltd
Protomer Technologies Inc
Rezolute Inc
Twist Bioscience Corp
USV Pvt Ltd
Xeris Biopharma Holdings Inc
Zealand Pharma AS
Zosano Pharma Corp
Zucara Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoglycemia – Overview

Hypoglycemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoglycemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoglycemia – Companies Involved in Therapeutics Development

Avolynt Inc

Boehringer Ingelheim International GmbH

Covis Pharmaceuticals Inc

CymaBay Therapeutics Inc

Eiger BioPharmaceuticals Inc

LATITUDE Pharmaceuticals Inc

NB Health Laboratory Co Ltd

Protomer Technologies Inc

Rezolute Inc

Twist Bioscience Corp

USV Pvt Ltd

Xeris Biopharma Holdings Inc

Zealand Pharma AS

Zosano Pharma Corp

Zucara Therapeutics Inc

Hypoglycemia – Drug Profiles

avexitide acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

AVO-3235 – Drug Profile

Product Description

Mechanism Of Action

dasiglucagon – Drug Profile

Product Description

Mechanism Of Action

History of Events

empagliflozin – Drug Profile

Product Description

Mechanism Of Action

History of Events

glucagon – Drug Profile

Product Description

Mechanism Of Action

History of Events

glucagon – Drug Profile

Product Description

Mechanism Of Action

History of Events

glucagon – Drug Profile

Product Description

Mechanism Of Action

glucagon – Drug Profile

Product Description

Mechanism Of Action

History of Events

glucagon – Drug Profile

Product Description

Mechanism Of Action

glucagon biosimilar – Drug Profile

Product Description

Mechanism Of Action

MBX-2982 – Drug Profile

Product Description

Mechanism Of Action

History of Events

P-017 – Drug Profile

Product Description

Mechanism Of Action

Rescue-G – Drug Profile

Product Description

Mechanism Of Action

RZ-358 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TB-013 – Drug Profile

Product Description

Mechanism Of Action

ZT-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Hypoglycemia – Dormant Projects

Hypoglycemia – Discontinued Products

Hypoglycemia – Product Development Milestones

Featured News & Press Releases

Feb 15, 2022: Zealand Pharma completes enrollment in phase 3 trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)

Dec 16, 2021: Xeris Biopharma announces the availability of Ogluo in the UK through its commercialization partner, Tetris Pharma

Sep 22, 2021: Rezolute presents results from two-week natural history study in congenital hyperinsulinism patients on standard of care therapies at ESPE 2021

Aug 23, 2021: Xeris Pharmaceuticals announces approval of supplemental new drug application (sNDA) of Gvoke Kit for the treatment of severe hypoglycemia

Aug 12, 2021: Zealand Pharma launches ZEGALOGUE (dasiglucagon) injection and advances pipeline programs across multiple therapeutic areas

Aug 05, 2021: Eiger announces FDA Breakthrough Therapy Designation for Avexitide for treatment of congenital hyperinsulinism

Jul 28, 2021: Zucara Therapeutics doses first patients in phase 1b trial of ZT-01

Jun 28, 2021: Eiger BioPharmaceuticals announces presentation of positive phase 2 results of avexitide in congenital hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session

Jun 24, 2021: Zealand Pharma announces U.S. commercial availability of ZEGALOGUE (dasiglucagon) injection

Jun 16, 2021: Zealand Pharma to present data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions

May 26, 2021: Zucara Therapeutics successfully completes single and multiple ascending dose phase 1 trial of ZT-01

May 12, 2021: Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue (dasiglucagon) injection

May 03, 2021: Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes

Apr 29, 2021: Xeris Pharmaceuticals receives U.K. MHRA approval of Ogluo (glucagon) Injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus

Mar 22, 2021: Rezolute presents data on RZ358 in post-gastric bypass hypoglycemia at ENDO 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Hypoglycemia, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hypoglycemia – Pipeline by Avolynt Inc, 2022

Hypoglycemia – Pipeline by Boehringer Ingelheim International GmbH, 2022

Hypoglycemia – Pipeline by Covis Pharmaceuticals Inc, 2022

Hypoglycemia – Pipeline by CymaBay Therapeutics Inc, 2022

Hypoglycemia – Pipeline by Eiger BioPharmaceuticals Inc, 2022

Hypoglycemia – Pipeline by LATITUDE Pharmaceuticals Inc, 2022

Hypoglycemia – Pipeline by NB Health Laboratory Co Ltd, 2022

Hypoglycemia – Pipeline by Protomer Technologies Inc, 2022

Hypoglycemia – Pipeline by Rezolute Inc, 2022

Hypoglycemia – Pipeline by Twist Bioscience Corp, 2022

Hypoglycemia – Pipeline by USV Pvt Ltd, 2022

Hypoglycemia – Pipeline by Xeris Biopharma Holdings Inc, 2022

Hypoglycemia – Pipeline by Zealand Pharma AS, 2022

Hypoglycemia – Pipeline by Zosano Pharma Corp, 2022

Hypoglycemia – Pipeline by Zucara Therapeutics Inc, 2022

Hypoglycemia – Dormant Projects, 2022

Hypoglycemia – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Hypoglycemia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Hypoglycemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.